Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB-2309
- Development stage
- Preclinical
- Lead developer
- PegBio
- Modality
- Peptides
01
Overview
PB-2309 is a synthetic peptide drug candidate developed by PegBio for the treatment of metabolic diseases. It acts as a triple agonist targeting the glucagon receptor (GCGR), gastric inhibitory polypeptide receptor (GIPR), and glucagon-like peptide 1 receptor (GLP-1R). The mechanism of action involves simultaneous activation of these three receptors, which are key regulators in glucose and energy metabolism. PB-2309 is being developed primarily for type 2 diabetes mellitus, with additional plans to pursue indications in non-alcoholic steatohepatitis (NASH) and obesity. As of June 2025, it remains in preclinical development[1][3][4][5].
02
Targets
Beyond the preview
Go deeper on PB-2309.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB-2309.